Unlocking Cellular Rejuvenation

A proprietary miRNA-based reprogramming platform that restores cellular youth and repairs DNA damage — enabling true longevity medicine.

At LIVIUS PTE. LTD., we are pioneering a new approach to biotechnology through cellular reprogramming.
Our proprietary platform uniquely combines miRNA-driven epigenetic control with small-molecule–induced reprogramming and DNA repair, enabling precise, scalable rejuvenation without genetic modification.

By bridging breakthrough R&D with real-world commercialization—from advanced cosmetic and dermatology-grade products to a growing therapeutic drug discovery pipeline—we deliver market-ready solutions that redefine the future of healthcare and longevity.

Company Story

About Us

LIVIUS PTE. LTD. was founded with a singular vision—to extend healthspan, not just lifespan, by addressing diseases that currently lack effective treatment at their biological roots.

Built on decades of hands-on experience across scientific research and commercial innovation, we advance a proprietary cellular reprogramming platform that integrates miRNA biology, small-molecule–based epigenetic control, and DNA repair. By working with the cell’s own regulatory mechanisms, our technology enables reproducible and scalable approaches to cellular rejuvenation.

This scientific foundation allows breakthrough research to translate seamlessly into real-world impact—from science-driven cosmetics and regulated non-prescription products to a growing therapeutic drug discovery pipeline. Headquartered in Singapore, with strategic operations in Japan, China and the United States, LIVIUS operates at the intersection of global research, clinical translation, and commercialization.

Technology

Core Science

miRNA-Driven Cellular Reprogramming

Through deep functional analysis of microRNAs (miRNAs), LIVIUS has established a proprietary approach to cellular reprogramming that operates through endogenous regulatory networks. By precisely modulating miRNA activity, we are able to induce controlled changes in cellular state without relying on transcription factor–based methods. This core scientific foundation enables stable and reproducible reprogramming while preserving cellular integrity.

Epigenetic Gene Expression

Small-Molecule Control of Cellular State

Building on our miRNA science, LIVIUS has developed a strategy to induce similar cellular reprogramming using small-molecule compounds. By epigenetically regulating target gene expression, these compounds activate the same biological pathways identified in our miRNA research. This chemically controlled approach offers high reproducibility, scalability, and a clear path toward real-world application, accelerating the transition from discovery to commercialization.

This advanced technological framework positions LIVIUS at the forefront of biotechnology, pioneering solutions that have the potential to transform the treatment landscape for many previously intractable diseases.

Epigenetic Gene Expression

Small-Molecule Control of Cellular State

Building on our miRNA science, LIVIUS has developed a strategy to induce similar cellular reprogramming using small-molecule compounds. By epigenetically regulating target gene expression, these compounds activate the same biological pathways identified in our miRNA research. This chemically controlled approach offers high reproducibility, scalability, and a clear path toward real-world application, accelerating the transition from discovery to commercialization.

This advanced technological framework positions LIVIUS at the forefront of biotechnology, pioneering solutions that have the potential to transform the treatment landscape for many previously intractable diseases.

Gene Mutation Repair

Evidence-Based DNA Damage Restoration

In parallel with cellular reprogramming, LIVIUS has confirmed—through experimental evidence—that DNA damage and gene mutations can be repaired during the reprogramming process. This simultaneous restoration of genomic integrity represents a critical step toward addressing diseases driven by genetic alterations. Establishing this capability as a therapeutic modality could open new possibilities for treating conditions rooted in accumulated DNA damage and mutation.

Products & Pipeline

Drug Discovery Pipeline

Our drug discovery pipeline is a dynamic portfolio of ongoing projects and clinical research initiatives aimed at transforming previously unsolvable diseases.

Commercialized Products

LIVIUS has successfully translated our cutting-edge technology into a range of market-ready products. Our commercial offerings include innovative cosmetic formulations and quasi-drugs.

Case Studies

We believe in evidence-based success. Our case studies highlight real-world examples of how our technology has delivered tangible benefits. For instance, one case study demonstrates.

Blog

News & Media

Get in touch

We’d love to hear from you

For all corporate inquiries, investor relations, and media requests, please reach out to us at:

Singapore Headquarters

#133 Cecil Street, #15-02 Keck Seng Tower, 069535 Singapore

Singapore R&D Center

#41 Science Park Road #04-12 The Gemini Singapore Park II Singapore 117610

Japan Office

#7F, Caterina Yanagidori, 1-18-10 Shinjuku, Shinjuku-ku, Tokyo, 160-0022, JAPAN

United States Office

For our U.S. operations, please contact us directly to obtain the relevant office details.

Follow our social network

Inquiry Form

If you have any questions or would like more information about our work, please fill out our simple inquiry form on our website. We value your feedback and will respond promptly to ensure your inquiries are addressed efficiently.